{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:23:16Z","timestamp":1782476596191,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,30]]},"DOI":"10.7759\/cureus.109913","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:57:29Z","timestamp":1780131449000},"source":"Crossref","is-referenced-by-count":1,"title":["Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) in a High-Risk Rheumatoid Arthritis Patient on Long-Term Baricitinib: Drug Signal or Risk Factor Convergence?"],"prefix":"10.7759","author":[{"given":"Ali D","family":"Alghaithi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid A","family":"Alnaqbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06762-x","article-title":"Cardiovascular manifestations and comorbidities in rheumatic diseases: perspectives on timely diagnosis, prevention, and treatment","volume":"42","author":"Gasparyan AY","year":"2023","unstructured":"Gasparyan AY. Cardiovascular manifestations and comorbidities in rheumatic diseases: perspectives on timely diagnosis, prevention, and treatment. Clin Rheumatol. 2023, 42:2531-3. 10.1007\/s10067-023-06762-x","journal-title":"Clin Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor PC","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, et al.. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019, 71:1042-55. 10.1002\/art.40841","journal-title":"Arthritis Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152461","article-title":"Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports","volume":"67","author":"Goldman A","year":"2024","unstructured":"Goldman A, Galper BL, Druyan A, et al.. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports. Semin Arthritis Rheum. 2024, 67:152461. 10.1016\/j.semarthrit.2024.152461","journal-title":"Semin Arthritis Rheum"},{"key":"ref4","unstructured":"European Medicines Agency. Olumiant. (2017). Accessed. May 22, 2026: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ph12010037","article-title":"Baricitinib: a 2018 novel FDA-approved small molecule inhibiting Janus kinases","volume":"12","author":"Mayence A","year":"2019","unstructured":"Mayence A, Vanden Eynde JJ. Baricitinib: a 2018 novel FDA-approved small molecule inhibiting Janus kinases. Pharmaceuticals (Basel). 2019, 12:37. 10.3390\/ph12010037","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70081","article-title":"Understanding cardiovascular events with JAK inhibitors: similarities and differences of the vascular effects between different JAK inhibitors on endothelial cells exposed to inflammatory cytokines","volume":"7","author":"Zavoriti A","year":"2025","unstructured":"Zavoriti A, Miossec P. Understanding cardiovascular events with JAK inhibitors: similarities and differences of the vascular effects between different JAK inhibitors on endothelial cells exposed to inflammatory cytokines. ACR Open Rheumatol. 2025, 7:e70081. 10.1002\/acr2.70081","journal-title":"ACR Open Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard L","year":"2022","unstructured":"Hoisnard L, Lebrun-Vignes B, Maury S, et al.. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022, 12:7140. 10.1038\/s41598-022-10777-w","journal-title":"Sci Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322849","article-title":"Cardiovascular safety of Janus kinase inhibitors: a pharmacovigilance study from 2012-2023","volume":"20","author":"Zhong X","year":"2025","unstructured":"Zhong X, Luo J, Huang Y, Wang S, Huang Y. Cardiovascular safety of Janus kinase inhibitors: a pharmacovigilance study from 2012-2023. PLoS One. 2025, 20:e0322849. 10.1371\/journal.pone.0322849","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca R","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, et al.. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis. 2017, 76:17-28. 10.1136\/annrheumdis-2016-209775","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox J","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017, 357:j2099. 10.1136\/bmj.j2099","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf168","article-title":"Performance of four cardiovascular risk scales in chronic inflammatory rheumatic disease patients: 10-year follow-up data","volume":"64","author":"Llorca J","year":"2025","unstructured":"Llorca J, Casta\u00f1eda S, Ferraz-Amaro I, et al.. Performance of four cardiovascular risk scales in chronic inflammatory rheumatic disease patients: 10-year follow-up data. Rheumatology (Oxford). 2025, 64:4227-35. 10.1093\/rheumatology\/keaf168","journal-title":"Rheumatology (Oxford)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead211","article-title":"Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis","volume":"62","author":"Campanaro F","year":"2023","unstructured":"Campanaro F, Zaffaroni A, Cacioppo E, et al.. Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis. Rheumatology (Oxford). 2023, 62:3245-55. 10.1093\/rheumatology\/kead211","journal-title":"Rheumatology (Oxford)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese MC","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, et al.. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016, 374:1243-52. 10.1056\/NEJMoa1507247","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor PC","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, et al.. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022, 81:335-43. 10.1136\/annrheumdis-2021-221276","journal-title":"Ann Rheum Dis"},{"key":"ref16","unstructured":"World Health Organization. VigiAccess. Accessed. May 27, 2026: https:\/\/www.vigiaccess.org\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.31204","article-title":"Comparative safety of JAK inhibitors vs TNF antagonists in immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"8","author":"Solitano V","year":"2025","unstructured":"Solitano V, Ahuja D, Lee HH, et al.. Comparative safety of JAK inhibitors vs TNF antagonists in immune-mediated inflammatory diseases: a systematic review and meta-analysis. JAMA Netw Open. 2025, 8:e2531204. 10.1001\/jamanetworkopen.2025.31204","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07360-9","article-title":"Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022","volume":"44","author":"Mikaeili B","year":"2025","unstructured":"Mikaeili B, Alqahtani ZA, Hincapie AL, Guo JJ. Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022. Clin Rheumatol. 2025, 44:1467-74. 10.1007\/s10067-025-07360-9","journal-title":"Clin Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000550737","article-title":"Cardiovascular adverse events of Jak versus TNF inhibitors using the Korean Pharmacovigilance database","author":"Yoon J","year":"2026","unstructured":"Yoon J, Kim S, Yang BR. Cardiovascular adverse events of Jak versus TNF inhibitors using the Korean Pharmacovigilance database. Cardiology. 2026, 1-10. 10.1159\/000550737","journal-title":"Cardiology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea JJ","year":"2012","unstructured":"O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012, 36:542-50. 10.1016\/j.immuni.2012.03.014","journal-title":"Immunity"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-019-0994-7","article-title":"Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"18","author":"Qiu C","year":"2019","unstructured":"Qiu C, Zhao X, She L, et al.. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2019, 18:54. 10.1186\/s12944-019-0994-7","journal-title":"Lipids Health Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02281-4","article-title":"A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19","volume":"39","author":"Bieber T","year":"2022","unstructured":"Bieber T, Feist E, Irvine AD, et al.. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022, 39:4910-60. 10.1007\/s12325-022-02281-4","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2026.152946","article-title":"Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings","volume":"77","author":"Mongin D","year":"2026","unstructured":"Mongin D, Aymon R, Choquette D, et al.. Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings. Semin Arthritis Rheum. 2026, 77:152946. 10.1016\/j.semarthrit.2026.152946","journal-title":"Semin Arthritis Rheum"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206690","article-title":"Janus kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib","volume":"12","author":"Harrington R","year":"2023","unstructured":"Harrington R, Harkins P, Conway R. Janus kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib. J Clin Med. 2023, 12:6690. 10.3390\/jcm12206690","journal-title":"J Clin Med"},{"key":"ref25","unstructured":"EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. (2022). Accessed. May 22, 2026: https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-...."},{"key":"ref26","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. (2022). Accessed. May 22, 2026: https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-e...."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03161-3","article-title":"Real-world evidence for baricitinib in the treatment of rheumatoid arthritis in Spain: a systematic literature review","volume":"42","author":"Rosas J","year":"2025","unstructured":"Rosas J, Belzunegui J, Hern\u00e1ndez-Cruz B, Aguirregabiria I, Moyano S, Cobo A, D\u00edaz-Cerezo S. Real-world evidence for baricitinib in the treatment of rheumatoid arthritis in Spain: a systematic literature review. Adv Ther. 2025, 42:2403-28. 10.1007\/s12325-025-03161-3","journal-title":"Adv Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.927","article-title":"Retrospective analysis of cardiovascular and malignancy risk factors in real world JAK inhibitor cohort and the effects of UK regulatory agency guidance cautioning JAK inhibitor use on prescribing","volume":"84","author":"Fitton J","year":"2025","unstructured":"Fitton J, Di Matteo A, Bissell LA, et al.. Retrospective analysis of cardiovascular and malignancy risk factors in real world JAK inhibitor cohort and the effects of UK regulatory agency guidance cautioning JAK inhibitor use on prescribing. Ann Rheum Dis. 2025, 84:751-2. 10.1016\/j.ard.2025.05.927","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/500327-non-st-segment-elevation-myocardial-infarction-nstemi-in-a-high-risk-rheumatoid-arthritis-patient-on-long-term-baricitinib-drug-signal-or-risk-factor-convergence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:57:31Z","timestamp":1780131451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/500327-non-st-segment-elevation-myocardial-infarction-nstemi-in-a-high-risk-rheumatoid-arthritis-patient-on-long-term-baricitinib-drug-signal-or-risk-factor-convergence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.109913","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,30]]}}}